|

Our firm has extensive experience
in research, development and production of products
derived from mammalian cell substrates, e.g. monoclonal
antibodies and recombinant proteins. We also have
experience with cell and gene therapy modalities.
W. Tolbert is an inventor on 26 US
Patents related to
cell culture technology and to
cell derived products. For 10 years he held
vice president positions in emerging and
mature biotechnology companies with responsibility for
technology, quality, process and product development.
 |
Regulatory compliance
associated with manufacturing is a distinct area of
our experience. We have assisted a number of
clients in recognizing
and addressing manufacturing cGMP/QSR issues.
We also participate in the planning, preparation and
agency review of comparability protocols for
manufacturing changes. |
 |
For organizations planning their first clinical or commercial product, we may
be of assistance in the challenging conversion of
research and/or laboratory scale processes into
commercially feasible manufacturing processes.
During scale-up, there are often a number of
possible development directions to attain the
quantities of product required for the next
pre-clinical or clinical phase. However, it is
critical to choose the technology and process
direction that will be most comparable with the
future commercial process. We are able to
assist companies and academic organizations plan
their technology and production advances to be most
suitable both for efficient production and for
regulatory compliance. |
 |
Patient-specific products
present particular challenges for "scale-up" or in
most cases "scale-out." Many production
processes are workable at a level sufficient to
treat from ten to 30 patients during initial
clinical development but may not be feasible for the
numbers of patients required in Phase 3 or for
commercial operation. We have experience in
the detailed analysis and modeling of production
processes to determine which methods may be most
suitable for both clinical and commercial
operations. In addition these products are
often very labor and facility intensive, requiring
extensive planning to be successful. FDA
issues and concerns related to mix-up and to
microbial contamination or contamination with
adventitious viral agents necessitate specific
aseptic processing controls. |
 |
We also provide
"trouble-shooting" and problem solving services for
existing manufacturing programs. It is often
very helpful to have an outside specialist review a
production program for discovery of inefficiencies,
problems or potential problems. Contamination
or cell viability problems are common instances
where our extensive experience has been helpful in
resolving production issues. |
Top of Page |